A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
BMC Urology Aug 30, 2017
Kim HS, et al. – The clinicians wished to examine the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate–resistant prostate cancer (CRPC). They concluded that the biweekly reduced dose docetaxel regimen was active and well–tolerated in Korean patients with metastatic CRPC.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
